Regeneron Pharmaceuticals Inc. Acquires 23andMe in Court-Supervised Sale

Regeneron Pharmaceuticals, Inc., a leading biopharmaceutical company based in Tarrytown, United States, has entered into an asset purchase agreement to acquire 23andMe® for $256 million. This acquisition, announced on May 19, 2025, aims to maintain the consumer genetics business and advance shared goals of improving human health and wellness. The purchase is subject to bankruptcy court and regulatory approvals, with Regeneron prioritizing the privacy, security, and ethical use of 23andMe’s customer data. The company has expressed readiness to work with an independent, court-appointed Customer Privacy Ombudsman.

Regeneron’s Market Performance

As of May 15, 2025, Regeneron’s stock closed at $594.32, with a 52-week high of $1,211.2 on August 26, 2024, and a low of $520.5 on May 7, 2025. The company’s market capitalization stands at $63.16 billion, with a price-to-earnings ratio of 14.89. On May 16, 2025, the stock experienced minimal price movement, trading at $588.35.

Regeneron’s Commitment to Science and Education

Regeneron continues to support scientific innovation through its 75th Annual Regeneron International Science and Engineering Fair, which awarded over $9 million to teen scientists from around the world. The competition, held in Columbus, Ohio, saw Adam Kovalčík, a 19-year-old participant, receive the $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections.

Legal Victory for Regeneron

In a significant legal development, Regeneron won over $400 million in a jury award as Amgen was found liable in an antitrust case. This victory underscores Regeneron’s strong position in the biotechnology industry.

Dividend Reminder

On May 20, 2025, Regeneron Pharmaceuticals, along with PROG Holdings and Prudential Financial, will trade ex-dividend for their respective upcoming dividends.

Regeneron Pharmaceuticals, Inc. remains a key player in the biotechnology sector, with a focus on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. The acquisition of 23andMe is expected to enhance Regeneron’s capabilities in genetic research and drug development.